Information on Viral Hepatitis from the National Institutes of Health
Viral hepatitis is inflammation of the liver caused by a virus. Several different viruses, named the hepatitis A, B, C, D, and E viruses, cause viral hepatitis. Read more at the National Institutes of Health. View more at the National Institutes of Health.
Information on Toxic Hepatitis from the University of Pittsburgh Medical Center
Hepatitis is inflammation of the liver. Toxic hepatitis refers to inflammation of the liver due to medication or exposure to toxic (poisonous) chemicals. Inflammation is a response by the immune system to an infection, irritation, or injury that often results in swelling and harm to the affected tissue. View more at the University of Pittsburgh Medical Center.
Information on Alcoholic Hepatitis at Mayo Clinic
Information on alcoholic hepatitis at the MayoClinic.com.
Information on Autoimmune Hepatitis from The National Digestive Diseases Information Clearinghouse
Autoimmune hepatitis is a disease in which the body’s immune system attacks liver cells. This immune response causes inflammation of the liver, also called hepatitis. Researchers think a genetic factor may make some people more susceptible to autoimmune diseases. About 70 percent of those with autoimmune hepatitis are female. The disease is usually quite serious and, if not treated, gets worse over time. Autoimmune hepatitis is typically chronic, meaning it can last for years, and can lead to cirrhosis—scarring and hardening—of the liver. Eventually, liver failure can result. View more at The National Digestive Diseases Information Clearinghouse, National Institutes of Health.
Quiz: Hepatitis C
This quiz will help you learn more about the hepatitis C virus. First, read each statement and answer "true" or "false." Then read more about the correct answer. Presented by the Department of Veterans Affairs
Quiz: Hepatitis B
How much do you know about hepatitis B? Take this quiz at hepatitisinfo.org and find out.
Quiz: Hepatitis A
Take the interactive quiz at the Virginia Department of Health.
Tutorial: Learning Guide - Living with Hepatitis B
Visit a new interactive learning guide developed by the Hepatitis B Foundation.
Video: Hepatitis 101
Knowledge is the key to prevention: Acting on lessons learned is essential! This unique tutorial describes ‘tried and true’, effective and easy-to-communicate messages about liver wellness, and the prevention of viral hepatitis and substance abuse. View the video at the Hepatitis Foundation International.
Video: Respect Yourself Protect Yourself
This 9 minute video is filling a tremendous void in information about the importance of the liver, ways to protect it and the transmission of viral hepatitis. It encourages viewers to take responsibility for their own health care including avoiding liver damaging activities such as injecting drugs, possible exposure to blood borne pathogens through body piercing, tattooing, and drinking alcohol. View the video at the Hepatitis Foundation International.
Screening for hepatitis C in adults: recommendation statement.
The USPSTF found good evidence that screening with available tests can detect HCV infection in the general population. The prevalence of HCV infection in the general population is low, and most who are infected do not develop cirrhosis or other major negative health outcomes. There is no evidence that screening for HCV infection leads to improved long-term health outcomes, such as decreased cirrhosis, hepatocellular cancer, or mortality. Although there is good evidence that anti-viral therapy improves intermediate outcomes, such as viremia, there is limited evidence that such treatment improves long-term health outcomes. View the major recommendations from the National Guideline Clearinghouse.
Recommendations for identification and public health management of persons with chronic hepatitis B virus infection.
Persons who are most likely to be actively infected with hepatitis B virus (HBV) should be tested for chronic HBV infection. Testing should include a serologic assay for hepatitis B surface antigen (HBsAg) offered as a part of routine care and be accompanied by appropriate counseling and referral for recommended clinical evaluation and care. View the major recommendations from the National Guideline Clearinghouse.
Free Full Text: Hepatitis C comorbidities affecting the course and response to therapy.
Several studies have demonstrated that the outcome of chronic hepatitis C (CHC) infection is profoundly influenced by a variety of comorbidities. Many of these comorbidities have a significant influence on the response to antiviral therapy. View the free full text at Pubmed.
Free Full Text: Approach to diagnosis of auto-immune hepatitis.
Auto-immune hepatitis (AIH) is one of the chronic liver diseases, seen predominantly in women, resulting from dysregulated immune mechanisms not yet clearly defined. Based on a combination of clinical and laboratory parameters with both positive and negative weights, the International AIH Group devised a scoring system in 1993. The system was modified in 1999 and has proven useful for both diagnostic and research purposes. This review deliberates on the clinical, immunological and histological features of this entity. View the free full text at Pubmed.
Free Full Text: Occult hepatitis B infection and its possible impact on chronic hepatitis C virus infection.
As a well-recognized clinical phenomenon, persistent detectable viral genome in liver or sera in the absence of other serological markers for active hepatitis B virus (HBV) replication is called occult HBV infection. The probable impact of occult HBV in patients with chronic HCV infection has been previously investigated and the evidence suggests a possible correlation with lower response to anti-viral treatment, higher grades of liver histological changes, and also developing hepatocellular carcinoma. View the free full text at Pubmed.
Free Full Text: Managing pediatric hepatitis C: current and emerging treatment options
Since 1992, the maternal–fetal route of transmission has become the dominant route for acquisition of hepatitis C (HCV) infection by children. Although children clearly have a milder degree of liver pathology, data have indicated that hepatic inflammation from HCV infection can progress to fibrosis or cirrhosis in children. In this article, recent improvements in therapy of children with CHC and in the clinical development of new emerging drugs with potential use in children will be reviewed. View the free full text at Pubmed.
Abstract: The characteristics of acute kidney injury complicated in acute hepatitis A.
Contrary to our expectations, acute kidney injury (AKI) is not an unusual complication in patients with acute hepatitis A (AHA). The objective of this study was to describe the clinical characteristics and risk factors for AKI in adults with AHA. In conclusion, more attention should be paid to whether AKI develops in patients with AHA, especially in patients with risk factors, and strategies to prevent AHA in adults should be considered carefully. View the abstract at Pubmed.
Free Full Text: DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target.
The use of DNA plasmids for DNA vaccination was first described in the early 1990s. DNA vaccination may be a useful therapy for chronic hepatitis C virus (HCV) infections. . The genetic variability of HCV, its immunomodulatory properties and high replication rate contribute to chronicity.The vaccination is intended to induce a coordinated immune-based attack on the continuously moving HCV target. If effective, this should help in clearing the infection. View the free full text at Pubmed.
Abstract: The option of liver transplantation for hepatitis B: where are we?
Combination therapy with hepatitis B immunoglobulin (HBIG) plus nucleus(t)ide analogue have reduced the rate of hepatitis B virus (HBV) recurrence post-transplantation to less than 10% at long-term. HBV recurrence diagnosed after 3 years post-transplantation is extremely rare. Considering the cost and the constraints of HBV prophylaxis it was suggested to decrease the amount of HBIG given and possibly to discontinue HBIG administration. The additional debate was on the need to maintain or not any HBV prophylaxis at long-term or to maintain monoprophylaxis with one or two nucleos(t)ide analogues or to administer HBV vaccine. View the abstract at Pubmed.
Looking for a Top-Rated
Gastroenterologist or Internist?
Consumers' Guide to Top Doctors finds the Doctors Rated Best by other Doctors
To find out who the top doctors are around the country, nonprofit Consumers' CHECKBOOK surveyed roughly 340,000 physicians to tell us which specialists they would want to care for a loved one. The Top Doctors database contains the names of over 23,000 doctors who were mentioned most often. Find top-rated doctors in the fifty largest metropolitan areas, in over thirty-five specialties, and more.
A downloadable brochure on hepatitis
Source:American Association of Gastroenterology
Viral Hepatitis Chart
Source: Wikimedia
Consumers' Guide to Top Doctors finds the Doctors Rated Best by other Doctors in over 30 specialties.
Search Top Doctors
database of 23,000 top-rated physicians by
Doctor's Name
Search Top
Doctors database of 23,000 top-rated
physicians by Specialty
Liver Location
Source: Wikimedia
Consumers' Guide to Hospitals
Which Hospital Should You Choose
"What makes the Consumers' Guide to Hospitals so special?
We've got 30 million answers to that question. That's how many hospital records Consumers' CHECKBOOK sifted through to calculate risk-adjusted death rates and adverse-outcome rates, and that's just part of the data used to rate the hospitals. The organization also sent out more than 280,000 questionnaires to physicians in 53 major metropolitan areas in the United States, asking them to rate their local hospitals; checked ratings of the hospitals by surveyed consumers; checked which hospitals were providing recommended tests and procedures for patients with specified medical problems; and more."
AARP The Magazine
Are you number 12?
Source: World Hepatitis Alliance
